Huaren Pharmaceutical: Announcement regarding the approval notice for the listing application of the wholly-owned subsidiary's active pharmaceutical ingredient Ketoprofen.
Huaren Pharmaceutical: Announcement regarding the acquisition of pharmaceutical registration certificate for the wholly-owned subsidiary Ketokonkalin Injection.
Huaren Pharmaceutical: Notice on Pre-Disclosure of Shareholding Reduction Plan by Shareholders Holding More Than 5% of Shares
Huaren Pharmaceutical: Announcement regarding wholly-owned subsidiary obtaining registration certificate for medical instruments.
Huaren Pharmaceutical: Announcement of Annual Equity Distribution Implementation in 2023
Huaren Pharmaceutical: Announcement regarding termination of the previous plan for change of controlling shareholder and initiation of a new plan for change of controlling shareholder.
Huaren Pharmaceutical: Announcement regarding the acquisition of pharmaceutical supplementary application approval for peritoneal dialysis solution (lactate-G1.5%, G2.5%).
Huaren Pharmaceutical: Announcement regarding the subsidiary's recertification as a high-tech enterprise.
Huaren Pharmaceutical: Announcement regarding wholly-owned subsidiary obtaining registration certificate for medical instruments.
Huaren Pharmaceutical: Notice on the wholly-owned subsidiary salbutamol sulfate injection obtaining a drug registration certificate
Huaren Pharmaceutical: ZTE Certified Public Accountants (Special General Partnership) Accountants Opinions on Huaren Pharmaceutical Co., Ltd.'s response to the 2023 Annual Report Inquiry Letter
Huaren Pharmaceutical: Announcement on the response to the inquiry letter on the annual report of the Shenzhen Stock Exchange
Huaren Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Huaren Pharmaceutical: Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2023 Annual General Meeting of Shareholders of Huaren Pharmaceutical Co., Ltd.
Huaren Pharmaceutical: Notice on Obtaining Approval Notice for Low-Calcium Peritoneal Dialysis Solution (Lactate-G 1.5%, G 2.5%, G 4.25%)
Huaren Pharmaceutical: Notice on the delay in responding to the Shenzhen Stock Exchange Annual Report Inquiry Letter
Huaren Pharmaceutical: Announcement on the subsidiary obtaining a medical device registration certificate
Huaren Pharmaceutical: 300110 Huaren Pharmaceutical Investor Relations Management Information 20240429
Huaren Pharmaceutical: Notice on the Wholly-owned Subsidiary Peritoneal Dialysis Solution (Lactate-G 4.25%) Obtaining an Approval Notice for Drug Supplementation Applications
Huaren Pharmaceutical: Announcement on terminating the issuance of A-shares to specific targets in 2023
No Data